ProQR Therapeutics N.V.

corporate_fare Company Profile

ProQR Therapeutics N.V.

PRQR·NASDAQ·Life Sciences·CIK 0001612940

ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on discovering and developing new therapeutic medicines. The company develops an RNA editing platform using its Axiomer RNA editing technology, aimed at treating genetic disorders where current treatments are insufficient. Its primary product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. ProQR also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. The company has a research and collaboration agreement with Eli Lilly and Company to discover, develop, and commercialize potential new medicines for genetic disorders affecting the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics N.V. (NASDAQ:PRQR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for PRQR at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

ProQR Nominates Pharma Veteran Dr. Lykke Hinsch Gylvin to Board of Directors (2026-04-30)
ProQR Details Expanded RNA Editing Pipeline, New Programs, and Clinical Milestones (2026-04-08)
ProQR Unveils Expanded Pipeline, Targets Multiple Clinical Data Readouts Through Mid-2027 (2026-04-08)
ProQR Partners with Ginkgo Bioworks, Forms AI Advisory Board to Accelerate RNA Drug Discovery (2026-04-08)
ProQR to Host Investor Event Highlighting Pipeline & Unveiling AX-0810 Primary Indication (2026-03-25)

Financial Snapshot

Fiscal year ended December 31, 2025

Revenue

€15.91M EUR

Net Income

-€42.18M EUR

Diluted EPS

-€0.40 EUR

Op. Cash Flow

-€52.79M EUR

Free Cash Flow

-€53.81M EUR

Operating Income

-€43.45M EUR

Cash & Equivalents

€92.41M EUR

Debt / Equity

0.00×

Net Margin

-265.2%

Source: 20-F · filed 2026-03-12 · accession 0001104659-26-026713

Insider Transactions

PRQR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

show_chartPrice Chart

Loading chart...

feed PRQR - Filings & News (Page 2)

Filing Type

Date Range

PRQR

Apr 30, 2026, 8:10 AM EDT

Filing Type: 6-K

Importance Score:

ProQR Nominates Pharma Veteran Dr. Lykke Hinsch Gylvin to Board of Directors

Price at Filing: $1.59

Real-time Price: $1.93

Change: +$0.340 (+21%)

Market Cap: $256.843M

Sentiment: Positive

View Wiseek Article

PRQR

Apr 08, 2026, 4:06 PM EDT

Filing Type: 6-K

Importance Score:

ProQR Details Expanded RNA Editing Pipeline, New Programs, and Clinical Milestones

Price at Filing: $1.93

Real-time Price: $1.93

Change: $0 (0%)

Market Cap: $256.843M

Sentiment: Positive

View Wiseek Article

PRQR

Apr 08, 2026, 4:00 PM EDT

Source: GlobeNewswire

Importance Score:

ProQR Unveils Expanded Pipeline, Targets Multiple Clinical Data Readouts Through Mid-2027

Price at Filing: $1.95

Real-time Price: $1.93

Change: -$0.020 (-1%)

Market Cap: $256.843M

Sentiment: Positive

View Wiseek Article

PRQR

Apr 08, 2026, 8:07 AM EDT

Filing Type: 6-K

Importance Score:

ProQR Partners with Ginkgo Bioworks, Forms AI Advisory Board to Accelerate RNA Drug Discovery

Price at Filing: $1.79

Real-time Price: $1.93

Change: +$0.140 (+8%)

Market Cap: $256.843M

Sentiment: Positive

View Wiseek Article

PRQR

Mar 25, 2026, 8:01 AM EDT

Filing Type: 6-K

Importance Score:

ProQR to Host Investor Event Highlighting Pipeline & Unveiling AX-0810 Primary Indication

Price at Filing: $1.52

Real-time Price: $1.93

Change: +$0.410 (+27%)

Market Cap: $256.843M

Sentiment: Neutral

View Wiseek Article

PRQR

Mar 12, 2026, 7:22 AM EDT

Filing Type: 20-F

Importance Score:

ProQR Therapeutics Reports Increased Net Loss and Declining Revenue for 2025

Price at Filing: $1.78

Real-time Price: $1.93

Change: +$0.150 (+8%)

Market Cap: $256.843M

Sentiment: Negative

View Wiseek Article

PRQR

Mar 12, 2026, 7:02 AM EDT

Source: Dow Jones Newswires

Importance Score:

ProQR Reports EUR0.40 Loss Per Share for 2025

Price at Filing: $1.78

Real-time Price: $1.93

Change: +$0.150 (+8%)

Market Cap: $256.843M

Sentiment: Negative

View Wiseek Article

PRQR

Mar 12, 2026, 7:00 AM EDT

Filing Type: 6-K

Importance Score:

ProQR Reports Increased 2025 Net Loss, €92.4M Cash with Runway into Mid-2027, Advances Key Pipeline Programs

Price at Filing: $1.78

Real-time Price: $1.93

Change: +$0.150 (+8%)

Market Cap: $256.843M

Sentiment: Neutral

View Wiseek Article

PRQR

Feb 06, 2026, 4:01 PM EST

Filing Type: SCHEDULE 13D/A

Importance Score:

Major Investor Van Herk Increases Stake in ProQR Therapeutics to 14.6% with $2.15M Share Purchase

Price at Filing: $1.50

Real-time Price: $1.93

Change: +$0.430 (+29%)

Market Cap: $256.843M

Sentiment: Positive

View Wiseek Article

PRQR

Jan 08, 2026, 8:08 AM EST

Filing Type: 6-K

Importance Score:

ProQR Reports Encouraging AX-0810 Phase 1 Safety Data, Advances Pipeline with Strong Preclinical Results, and Secures $4.5M Lilly Milestones

Price at Filing: $2.29

Real-time Price: $1.93

Change: -$0.360 (-16%)

Market Cap: $256.843M

Sentiment: Positive

View Wiseek Article

Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets

corporate_fare Company Profile